We use cookies for a better user experience. Read our Privacy Policy

I Agree

Industry Verticals »

All Categories

Insights »

About TMR »

Rheumatoid Arthritis Drugs Market

Schedule a Call

Rheumatoid Arthritis Drugs Market

Rheumatoid Arthritis Drugs Market (Drug Type - Disease-modifying Anti-rheumatic Drugs (DMARDs), Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids, Biologic Response Modifiers (Biologics); Distribution Channel - Hospital Pharmacy, Retail Pharmacy, Online Pharmacy - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Rheumatoid Arthritis Drugs Market: Overview

The rheumatoid arthritis drugs market expects a good turnover across the forecast period of 2018-2026 due to the increasing prevalence of rheumatoid arthritis among the global populace. Rheumatoid arthritis is a condition that affects the joints of the hand, wrists, ankles, and knees. It is categorized as a systemic disease as it also affects the respiratory and cardiac system. It is usually prevalent among the elderly and largely affects the female population. The symptoms of rheumatoid arthritis are warmth, redness, and swelling of the affected areas. Statistics highlight that 41 people out of 10000 people are diagnosed with rheumatoid arthritis.

The rheumatoid arthritis drugs market may gain an upper hand in growth mainly due to the escalating use of over-the-counter medications rather than surgeries or operations for treating rheumatoid arthritis. The drugs developed for curing rheumatoid arthritis can enhance prognosis and mobility greatly and serve as a boon for the patients. The aforementioned factors may bring great growth opportunities for the rheumatoid arthritis drugs market.

rheumatoid arthritis drugs

The COVID-19 outbreak may have minimal impact on the rheumatoid arthritis drugs market as the pharmaceutical sector is ruled out of the lockdown norms by the government. The production of drugs remains largely unaffected as the pharma sector is fully functional without any restrictions. Therefore, this factor may have a minimal negative influence on the rheumatoid arthritis drugs market. However, the post-lockdown era may assure stable growth for the rheumatoid arthritis drugs market.

The global rheumatoid arthritis drugs market was valued at US$ 19597.43 mn in 2016. Taking into consideration the factors associated with the growth of the rheumatoid arthritis drugs market, it is anticipated to expand at a CAGR of 2.96% from 2018 to 2026. The use of rheumatoid arthritis drugs to decrease joint damage and enhance the overall body functioning may serve as great growth generators for the rheumatoid arthritis drugs market.

Biologics Segment to Gain Considerable Momentum

Based on drug type, the rheumatoid arthritis drugs market can be segmented into nonsteroidal anti-inflammatory drugs (NSAIDs), anti-rheumatic drugs (DMARDs), biologic drugs, and corticosteroids. The biologics segment may acquire a significant share of the rheumatoid arthritis drugs market due to the advancements in biotechnological research. The spike in the use of biological drugs may also serve as a growth multiplier for the rheumatoid arthritis drugs market.

Hospital Pharmacy Segment to Contribute Significantly, Online Pharmacy to Gain Good Traction

In terms of the distribution channel, the rheumatoid arthritis drugs market can be classified into online pharmacy, retail pharmacy, and hospital pharmacy. Hospital pharmacy is estimated to observe good growth. Online pharmacy may also acquire a substantial growth share. The COVID-19 outbreak may serve as the prominent growth factor for the online pharmacy segment. Due to the growing transmission of the novel coronavirus and the stay-at-home orders by governments of various countries, many consumers are opting for online pharmacy methods to get their medicines at home.

Key Players to Gain Largely Due to Mergers and Acquisition Activities

Many key players are involved in activities such as mergers, acquisitions, joint ventures, partnerships, and collaborations to cement their base among all the competitors. This aspect eventually serves as a growth generator for the rheumatoid arthritis drugs market. The investment of prominent players in research and development activities may harness growth for the rheumatoid arthritis drugs market. Some well-entrenched players in the rheumatoid arthritis drugs market are Novartis AG, Hoffman-La Roche Ltd., Bristol-Myers Squibb Company, Pfizer Inc., and Eli Lilly and Company.

Use of Rheumatoid Arthritis Drugs in Treating COVID-19 May Serve As a Game-Changer for Growth

The novel coronavirus pandemic has created havoc across the globe with its escalating fatalities and high transmission rate. The race to find a vaccine or treatment for recovering from COVID-19 is in full force. Various governments and organizations are pumping investments in research and development activities. The potential of existing drugs to cure COVID-19 is also being explored by researchers and scientists.

Rheumatoid arthritis drugs are being tested for curing COVID-19. Tocilizumab, an immunosuppressive drug used for the treatment of rheumatoid arthritis is being tested. Another drug, baricitinib, used for treating rheumatoid arthritis is also being tested. If these tests are successful, they can turn the tables of growth for the rheumatoid arthritis drugs market.
Quick regulatory approvals and government support to fuel growth prospects of rheumatoid arthritis drugs market

The rheumatoid arthritis drugs market may gain largely from quick approvals for drugs from regulatory bodies like the FDA and the support of government through funding and legislation is anticipated to bring great growth prospects for the rheumatoid arthritis drugs market.

Asia Pacific to Emerge As Significant Growth Contributor

Geographically, the rheumatoid arthritis drugs market is segmented into North America, Latin America, the Middle East and Africa, Asia Pacific, and Europe. Asia Pacific is expected to emerge as a prominent market shareholder in terms of region. The accelerating healthcare expenditure and the presence of an extensive distribution system may bring good growth for the rheumatoid arthritis drugs market.

Small players are entering the rheumatoid arthritis drugs market, ultimately leading to a boost in the growth rate. Prominent key players are bolstering growth for the rheumatoid arthritis drugs market due to consumer loyalty. Low-cost manufacturing costs have led to a rise in production facilities related to pharmaceutical and biological organizations across India and China. North America may record a moderate rate due to the growing prevalence of rheumatoid arthritis and huge investments in the healthcare sector.   

The global rheumatoid arthritis drugs market has been segmented as given below:

Drug Type
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
  • Corticosteroids
  • Disease Modifying Anti-rheumatic Drugs (DMARDs)
  • Biologic Response Modifiers (Biologics)

 

Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Geography
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC countries
    • South Africa
    • Rest of Middle East & Africa

    1. Preface
         1.1. Report Scope and Market Segmentation
         1.2. Research Highlights

    2. Assumptions and Research Methodology
         2.1. Assumptions and Acronyms Used
         2.2. Research Methodology

    3. Executive Summary
         3.1. Global Rheumatoid Arthritis Drugs Market: Market Snapshot

    4. Market Overview
         4.1. Global Rheumatoid Arthritis Drugs Market: Product Overview
         4.2. Global Rheumatoid Arthritis Drugs Market: Key Industry Developments
         4.3. Market Dynamics
                4.3.1. Drivers
                4.3.2. Restraints
                4.3.3. Opportunities
         4.4. Global Rheumatoid Arthritis Drugs Market Revenue Projections, 2016–2026
         4.5. Porter’s Five Forces Analysis

    5. Market Outlook
         5.1. Pipeline analysis
         5.2. Brand Analysis
         5.3. Key Mergers and Acquisitions

    6. Global Rheumatoid Arthritis Drugs Market Analysis, by Drug Type
         6.1. Key Findings
         6.2. Introduction
         6.3. Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
         6.4. Global Rheumatoid Arthritis Drugs Market Value Forecast, by Drug Type
                6.4.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
                6.4.2. Corticosteroids
                6.4.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
                6.4.4. Biologic Response Modifiers (Biologics)
         6.5. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type

    7. Global Rheumatoid Arthritis Drugs Market Analysis, by Distribution Channel
         7.1. Key Findings
         7.2. Introduction
         7.3. Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channels
         7.4. Global Rheumatoid Arthritis Drugs Market Value Forecast, by Distribution Channel
                7.4.1. Hospital Pharmacy
                7.4.2. Retail Pharmacy
                7.4.3. Online Pharmacy
         7.5. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channels

    8. Global Rheumatoid Arthritis Drugs Market Analysis, by Region
         8.1. Key Findings
         8.2. Global Rheumatoid Arthritis Drugs Market Scenario, by Country
         8.3. Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Region
         8.4. Global Rheumatoid Arthritis Drugs Market Value Forecast, by Region
                8.4.1. North America
                8.4.2. Europe
                8.4.3. Asia Pacific
                8.4.4. Latin America
                8.4.5. Middle East & Africa
         8.5. Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Region

    9. North America Rheumatoid Arthritis Drugs Market Analysis
         9.1. Key Findings
         9.2. North America Rheumatoid Arthritis Drugs Market Overview
         9.3. North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
         9.4. North America Rheumatoid Arthritis Drugs Market Forecast, by Country
                9.4.1. U.S.
                9.4.2. Canada
         9.5. North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
         9.6. North America Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
                9.6.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
                9.6.2. Corticosteroids
                9.6.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
                9.6.4. Biologic Response Modifiers (Biologics)
         9.7. North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
         9.8. North America Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
                9.8.1. Hospital Pharmacy
                9.8.2. Retail Pharmacy
                9.8.3. Online Pharmacy
         9.9. North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis

    10. Europe Rheumatoid Arthritis Drugs Market Analysis
         10.1. Key Findings
         10.2. Europe Rheumatoid Arthritis Drugs Market Overview
         10.3. Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
         10.4. Europe Rheumatoid Arthritis Drugs Market Forecast, by Country
                10.4.1. Germany
                10.4.2. U.K.
                10.4.3. France
                10.4.4. Italy
                10.4.5. Spain
                10.4.6. Rest of Europe
         10.5. Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
         10.6. Europe Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
                10.6.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
                10.6.2. Corticosteroids
                10.6.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
                10.6.4. Biologic Response Modifiers (Biologics)
         10.7. Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
         10.8. Europe Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
                10.8.1. Hospital Pharmacy
                10.8.2. Retail Pharmacy
                10.8.3. Online Pharmacy
         10.9. Europe Rheumatoid Arthritis Drugs Market Attractiveness Analysis

    11. Asia Pacific Rheumatoid Arthritis Drugs Market Analysis
         11.1. Key Findings
         11.2. Asia Pacific Rheumatoid Arthritis Drugs Market Overview
         11.3. Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
         11.4. Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Country
                11.4.1. China
                11.4.2. India
                11.4.3. Japan
                11.4.4. Australia & New Zealand
                11.4.5. Rest of Asia Pacific
         11.5. Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
         11.6. Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
                11.6.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
                11.6.2. Corticosteroids
                11.6.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
                11.6.4. Biologic Response Modifiers (Biologics)
         11.7. Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
         11.8. Asia Pacific Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
                11.8.1. Hospital Pharmacy
                11.8.2. Retail Pharmacy
                11.8.3. Online Pharmacy
         11.9. Asia Pacific Rheumatoid Arthritis Drugs Market Attractiveness Analysis

    12. Latin America Rheumatoid Arthritis Drugs Market Analysis
         12.1. Key Findings
         12.2. Latin America Rheumatoid Arthritis Drugs Market Overview
         12.3. Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
         12.4. Latin America Rheumatoid Arthritis Drugs Market Forecast, by Country
                12.4.1. Brazil
                12.4.2. Mexico
                12.4.3. Rest of Latin America
         12.5. Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
         12.6. Latin America Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
                12.6.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
                12.6.2. Corticosteroids
                12.6.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
                12.6.4. Biologic Response Modifiers (Biologics)
                12.6.5. Enteral needles
         12.7. Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
                12.7.1. Hospital Pharmacy
                12.7.2. Retail Pharmacy
                12.7.3. Online Pharmacy
         12.8. Latin America Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
         12.9. Latin America Rheumatoid Arthritis Drugs Market Attractiveness Analysis

    13. Middle East & Africa Rheumatoid Arthritis Drugs Market Analysis
         13.1. Key Findings
         13.2. Middle East & Africa Rheumatoid Arthritis Drugs Market Overview
         13.3. Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country
         13.4. Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Country
                13.4.1. GCC Countries
                13.4.2. South Africa
                13.4.3. Rest of Middle East and Africa
         13.5. Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type
         13.6. Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Drug Type
                13.6.1. Nonsteroidal Anti-inflammatory Drugs (NSAIDS)
                13.6.2. Corticosteroids
                13.6.3. Disease Modifying Anti-rheumatic Drugs (DMARDs)
                13.6.4. Biologic Response Modifiers (Biologics)
         13.7. Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel
         13.8. Middle East & Africa Rheumatoid Arthritis Drugs Market Forecast, by Distribution Channel
                13.8.1. Hospital Pharmacy
                13.8.2. Retail Pharmacy
                13.8.3. Online Pharmacy
         13.9. Middle East & Africa Rheumatoid Arthritis Drugs Market Attractiveness Analysis

    14. Competitive Landscape
         14.1. Company Profiles
                14.1.1. AbbVie, Inc.
                         14.1.1.1. Company Details
                         14.1.1.2. Business Overview
                         14.1.1.3. Financial Overview
                         14.1.1.4. Strategic Overview
                         14.1.1.5. SWOT Analysis
                14.1.2. Janssen Biotech, Inc.
                         14.1.2.1. Company Details
                         14.1.2.2. Business Overview
                         14.1.2.3. Financial Overview
                         14.1.2.4. Strategic Overview
                         14.1.2.5. SWOT Analysis
                14.1.3. Amgen, Inc.
                         14.1.3.1. Company Details
                         14.1.3.2. Business Overview
                         14.1.3.3. Financial Overview
                         14.1.3.4. Strategic Overview
                         14.1.3.5. SWOT Analysis
                14.1.4. Pfizer, Inc.
                         14.1.4.1. Company Details
                         14.1.4.2. Business Overview
                         14.1.4.3. Financial Overview
                         14.1.4.4. Strategic Overview
                         14.1.4.5. SWOT Analysis
                14.1.5. Novartis AG
                         14.1.5.1. Company Details
                         14.1.5.2. Business Overview
                         14.1.5.3. Financial Overview
                         14.1.5.4. Strategic Overview
                         14.1.5.5. SWOT Analysis
                14.1.6. Sanofi S.A.
                         14.1.6.1. Company Details
                         14.1.6.2. Business Overview
                         14.1.6.3. Financial Overview
                         14.1.6.4. Strategic Overview
                         14.1.6.5. SWOT Analysis
                14.1.7. F. Hoffmann-La Roche Ltd.
                         14.1.7.1. Company Details
                         14.1.7.2. Business Overview
                         14.1.7.3. Financial Overview
                         14.1.7.4. Strategic Overview
                         14.1.7.5. SWOT Analysis
                14.1.8. Merck & Co.
                         14.1.8.1. Company Details
                         14.1.8.2. Business Overview
                         14.1.8.3. Financial Overview
                         14.1.8.4. Strategic Overview
                         14.1.8.5. SWOT Analysis
                14.1.9. Bristol-Myers Squibb Company
                         14.1.9.1. Company Details
                         14.1.9.2. Business Overview
                         14.1.9.3. Financial Overview
                         14.1.9.4. Strategic Overview
                         14.1.9.5. SWOT Analysis
                14.1.10. Eli Lilly and Company
                         14.1.10.1. Company Details
                         14.1.10.2. Business Overview
                         14.1.10.3. Financial Overview
                         14.1.10.4. Strategic Overview
                         14.1.10.5. SWOT Analysis

    List of Tables

    Table 01: Global Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2016–2026
    Table 02: Global Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 03: Global Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Region, 2016–2026
    Table 04: North America Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Country, 2018–2026
    Table 05: North America Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2016–2026
    Table 06: North America Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 07: Europe Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
    Table 08: Europe Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2016–2026
    Table 09: Europe Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 10: Asia Pacific Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
    Table 11: Asia Pacific Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2016–2026
    Table 12: Asia Pacific Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 13: Latin America Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
    Table 14: Latin America Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2016–2026
    Table 15: Latin America Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 16: Middle East & Africa Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
    Table 17: Middle East & Africa Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Drug Type, 2016–2026
    Table 18: Middle East & Africa Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026

    List of Figures

    Figure 01: Global Rheumatoid Arthritis Drugs Market Size (US$ Mn) Forecast, 2016–2026
    Figure 02: Global Rheumatoid Arthritis Drugs Market Value Share, by Drug Type (2017)
    Figure 03: Global Rheumatoid Arthritis Drugs Market Value Share, by Distribution Channel (2017)
    Figure 04: Global Rheumatoid Arthritis Drugs Market Value Share, by Region (2017)
    Figure 05: Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2018 and 2026
    Figure 06: Global Rheumatoid Arthritis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Disease-modifying Anti-rheumatic Drugs (DMARDs), 2016–2026
    Figure 07: Global Rheumatoid Arthritis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Non-steroidal Anti-inflammatory Drugs (NSAIDs), 2016–2026
    Figure 08: Global Rheumatoid Arthritis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Corticosteroids, 2016–2026
    Figure 09: Global Rheumatoid Arthritis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Biologics, 2016–2026
    Figure 10: Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2018–2026
    Figure 11: Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2026
    Figure 12: Global Rheumatoid Arthritis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacy, 2016–2026
    Figure 13: Global Rheumatoid Arthritis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacy, 2016–2026
    Figure 14: Global Rheumatoid Arthritis Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacy, 2015-2026
    Figure 15: Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
    Figure 16: Global Rheumatoid Arthritis Drugs Market Value Share Analysis, by Region, 2017 and 2026
    Figure 17: Global Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Region, 2018?2026
    Figure 18: North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
    Figure 19: North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2018 and 2026
    Figure 20: North America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2026
    Figure 21: North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2018–2026
    Figure 22: North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
    Figure 23: North America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country, 2018–2026
    Figure 24: Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
    Figure 25: Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2018 and 2026
    Figure 26: Europe Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2026
    Figure 27: Europe Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2018–2026
    Figure 28: Europe Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
    Figure 29: Europe Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
    Figure 30: Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
    Figure 31: Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2018 and 2026
    Figure 32: Asia Pacific Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2026
    Figure 33: Asia Pacific Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2018–2026
    Figure 34: Asia Pacific Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
    Figure 35: Asia Pacific Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
    Figure 36: Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
    Figure 37: Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2018 and 2026
    Figure 38: Latin America Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2026
    Figure 39: Latin America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2018–2026
    Figure 40: Latin America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
    Figure 41: Latin America Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
    Figure 42: Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Country/Sub-region, 2018 and 2026
    Figure 43: Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Drug Type, 2018 and 2026
    Figure 44: Middle East & Africa Rheumatoid Arthritis Drugs Market Value Share Analysis, by Distribution Channel, 2018 and 2026
    Figure 45: Middle East & Africa Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Drug Type, 2018–2026
    Figure 46: Middle East & Africa Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Distribution Channel, 2018–2026
    Figure 47: Middle East & Africa Rheumatoid Arthritis Drugs Market Attractiveness Analysis, by Country/Sub-region, 2018
    Figure 48: AbbVie, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
    Figure 49: AbbVie, Inc. R&D Expenses (US$ Mn) – Company Level, 2015–2017
    Figure 50: AbbVie, Inc. Breakdown of Net Sales (Surgical Products), by Region 2017
    Figure 51: AbbVie, Inc. Breakdown of Net Sales, by Business Segment, 2017
    Figure 52: Janssen Biotech, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2015–2017
    Figure 53: Janssen Biotech, Inc. R&D Expenses (US$ Mn) – Company Level, 2015–2017
    Figure 54: Janssen Biotech, Inc. Breakdown of Net Sales (Surgical Products), by Region 2017
    Figure 55: Janssen Biotech, Inc. Breakdown of Net Sales, by Business Segment, 2017
    Figure 56: Amgen, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
    Figure 57: Amgen, Inc. R&D Expenses (US$ Mn) – Company Level, 2015–2017
    Figure 58: Amgen, Inc. Breakdown of Net Sales (Surgical Products), by Region 2017
    Figure 59: Amgen, Inc. Breakdown of Net Sales, by Business Segment, 2017
    Figure 60: Pfizer, Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
    Figure 61: Pfizer, Inc. R&D Expenses (US$ Mn) – Company Level, 2015–2017
    Figure 62: Pfizer, Inc. Breakdown of Net Sales (Surgical Products), by Region 2017
    Figure 63: Pfizer, Inc. Breakdown of Net Sales, by Business Segment, 2017
    Figure 64: Novartis AG Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
    Figure 65: Novartis AG R&D Expenses (US$ Mn) – Company Level, 2015–2017
    Figure 66: Novartis AG Breakdown of Net Sales (Surgical Products), by Region 2017
    Figure 67: Novartis AG Breakdown of Net Sales, by Business Segment, 2017
    Figure 68: Sanofi S.A. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
    Figure 69: Sanofi S.A. R&D Intensity (%) 2015–2016
    Figure 70: Sanofi S.A. Breakdown of Net Sales, by Region, 2017
    Figure 71: Sanofi S.A. Breakdown of Net Sales, by Segment, 2017
    Figure 72: F. Hoffmann-La Roche Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2017
    Figure 73: F. Hoffmann-La Roche Ltd. R&D Intensity (US$ Mn), 2015–2017
    Figure 74: F. Hoffmann-La Roche Ltd. Breakdown of Net Sales, by Region, 2017
    Figure 75: F. Hoffmann-La Roche Ltd. Breakdown of Net Sales, by Segment, 2017
    Figure 76: Merck & Co., Inc. Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
    Figure 77: Merck & Co., Inc. R&D Intensity (US$ Mn), 2015–2017
    Figure 78: Merck & Co., Inc. Breakdown of Net Sales, by Region, 2016
    Figure 79: Merck & Co., Inc. Breakdown of Net Sales, by Segment, 2017
    Figure 80: Bristol-Myers Squibb Company Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2017
    Figure 81: Bristol-Myers Squibb Company R&D Intensity (US$ Mn), 2015–2017
    Figure 82: Bristol-Myers Squibb Company Breakdown of Net Sales, by Region, 2017
    Figure 83: Eli Lilly and Company Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2017
    Figure 84: Eli Lilly and Company R &D Intensity (US$ Mn), 2015–2017
    Figure 85: Eli Lilly and Company Breakdown of Net Sales, by Region (Company Level), 2017
    Figure 86: Eli Lilly and Company Breakdown of Net Sales, by Therapeutic Areas, 2017

Copyright © Transparency Market Research, Inc. All Rights reserved